International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 1 Jan-Feb 2024, pp: 1346-1350 www.ijprajournal.com ISSN: 2249-7781

Role of Statins in Diabetes Mellitus

Anusha D*, Maheshwari E, Tejasvini D
Department of physical pharmaceutics,
Malla Reddy Institute Of Pharmaceutical Sciences, Dhulapally, Maisammaguda, Hyderabad, Telengana 500100.

Submitted: 10-02-2024 Accepted: 19-02-2024

ABSTRACT: Statins, 3-hydroxy methyl glutaryl coenzyme A reductase inhibitors, are oDften used in primary and secondary prevention of cardiovascular disease to lower serum cholesterol levels.
Because type 2 diabetes is associated with Dyslipidemia, Statins play an important role in preventing long-term complications of diabetes. They are also recommended for diabetic patients with normal low-density lipoprotein levels.
Food and Drug Administration announced changes to the safety Labelling of statins, including that statins have been shown to increase glycosylated Haemoglobin and fasting serum glucose levels.
Numerous studies conducted in patients with cardiovascular risk factors have shown that statins have diabetes including potential and their effects vary depending on the dose and type used.
Various mechanisms have been proposed for this effect, one of which is the down-regulation of glucose transporters by statins.
The researcher's recommendation is that while statins may pose a risk of including diabetes, the longterm benefits may outweigh the risks. Statins should be used with caution in elderly patients and patients with metabolic syndrome because of the increased risk of diabetes. Statins still offer longterm survival benefits in most patients.
KEYWORDS: New onse1t diabetes mellitus, Statins, hyperglycemia, cardiovascular risk, dyslipidemia.

I. METHODOLOGY:

Long-term benefits of statin use in diabetics include a reduction in morbidity and mortality. Statins have been linked to an increased risk of new-onset diabetes, according to recent research. After the Food and Drug Administration published modifications to statin safety that raise blood glucose and glycosylated hemoglobin levels, the matter came under scrutiny. Statins are helpful in preventing cardiovascular events at the same time. The majority of researchers believe that the long-term advantages of preventing problems can outweigh the risk of diabetes when using statins. Statins should be used with caution in patients who are at risk of developing diabetes.

II. INTRODUCTION

Statins, 3-hydroxy-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors, inhibit the ratelimiting step in the conversion of HMG-CoA to mevalonate, thereby limiting cholesterol synthesis.
A decrease in cholesterol levels in the liver is followed by an increase in the expression of low-density lipoprotein (LDL) receptors in hepatocytes. This improves the clearance of LDL particles from blood.
Lowering plasma LDL- cholesteroll by statins reduces production and increase of catabolism of apo B 100.
A range of products like coenzyme Q10, Hem A, and Iso prenylated proteins, are generated through the mevalonate pathway and play an important role in cell biology and human physiology.
The roles of statins are widely considered to include inflammatory markers, nitric oxide (NO), polyunsaturated fatty acids, immunomodulation, neuroprotection, and cellular senescence, etc.

III. STATINS IN DIABETES

Cardiovascular disease can be prevented both primary and secondary with the use of statins. Statin`s pleiotropic effects, as opposed to their hypolipedimic characteristics, account for additional advantages. Statins have been shown to have pleiotropic effects that are not related to decreasing cholesterol in situations such as heart failure, arrhythmia, vascular disease, and hypertension. The suppression of Isoprenoid production, which suppresses intracellular signaling molecules Rho, Rac, and Cdc42, may be the cause of these statin-mediated pleiotropic effects. Rho inhibition and Rho activation of Rho kinase are the principal mechanisms proposed. Insulin resistance, Insulin insufficiency, and hyperglycemia are the hallmarks of type 2 diabetes. A typical lipid profile linked to type 2 diabetes is

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 1 Jan-Feb 2024, pp: 1346-1350 www.ijprajournal.com ISSN: 2249-7781

exacerbated by insulin resistance. Patients with type 2 diabetes are more likely to experience cardiovascular events when they have dyslipidemia.

Even if we exclude the baseline LDL, There is a linear correlation between diabetic cholesterol levels and cardiovascular illnesses. Statins appear to be helpful because they primarily decrease LDL cholesterol and have minimal impact on other lipoproteins. when compared to a placebo, The heart protection study, which involved diabetics, showed a 22% reduction in cardiovascular events such as stroke and first major coronary event. The American Diabetes Association advised medication was in those with diabetes and other cardiovascular risk factors if their goal LDL cholesterol levels 100 mg/dl additionally, researchers believe that the cardiovascular problems associated with diabetes should be the determining factor for statin medication, rather than LDL levels.

IV. STATINS AND DIABETES RISK

The Food and Drug Administration updated the safety label for statins in February 2012, noting that statins have been shown to raise fasting serum glucose levels and hemoglobin (HbA1C) levels. The use of statins in patients with cardiovascular risk factors, such as diabetes, has come under scrutiny due to this release.

Participants in the justification for the use of statins in Prevention: an Intervention Trail Evaluating Rosuvastatin study who had elevated sensitivity say C-reactive protein levels and LDL cholesterol levels less than 130mg/dl were included over the course of two years, were given either rosuvastatin or a placebo. When Rosuvastatin was compared to a placebo, it was found to significantly lower the rates of both first major cardiovascular events and death from any cause. The statin group was found to have a 54% lower risk of heart attack, a 20% lower risk of stroke, and a 20% lower risk of death from all causes. There was a reported race in new-onset diabetes, 2.4% in the placebo arm and 3% in the statin arm.

This was one of the first studies to document the rise in new-onset diabetes statin-using patients, and it was accompanied by an increase in the median value of glycated hemoglobin. In the post hoc analysis known as the Women's Health Initiative trial, 153840 postmenopausal women without diabetes mellitus were involved, There was a correlation between starting therapy and an elevated risk of newonset diabetes mellitus even after controlling for possible confounders.

A 9% increased risk of incident diabetes was linked to statin therapy, according to a meta-analysis of randomized controlled trials by Sattar et al. Involving 9140 non-diabetic patients. 255 patients received

treatment over a four-year period, but one additional case of diabetes mellitus was identified. The study conducted by the authors revealed that there was no discernible variation in the risk of diabetes between hydrophilic and lipophilic statins.

While some research suggested that this was a class effect., Other studies found that different statins and doses had different effects. Numerous studies demonstrated a dose-dependent relationship between statin use and the onset of diabetes. The risk of incident diabetes was compared between intensive and moderate-dose statin therapy in a meta-analysis involving 32752 participants it was discovered that while taking high doses of statins reduced cardiovascular events, they were also linked to a high incidence of diabetes mellitus. Compared to patients receiving moderate doses of statin therapy, 18.9 ± 5.2 diabetic cases per 1000 patient-years were absorbed in those receiving intensive doses of statin therapy.

3382 patients without a history of type 2 diabetes mellitus were included in the PROVE-IT TIMI 22 trial. Patients treated with 40 mg of pravastatin had an increase in HbA1c levels of 0.12%, whereas patients treated with 80mg of atorvastatin had a significant difference with increases in levels of 0.30%. Another study comparing the glycaemic level control of diabetic patients receiving pitavastatin 2 mg/d, pravastatin 10mg or atorvastatin 10mg/d revealed that the only patients whose HbA1c and blood glucose levels increased were those receiving atorvastatin. Compared to pravastatin, treatment with Atorvastatin and simvastatin may be linked to a higher risk of diabetes with a new onset.

V. MECHANISM OF STATINS IN HYPERGLYCEMIA

Insulin resistance brought on by statins may result from down-regulating the production of C/EBPα and inhibiting isoprenoid biosynthesis. Downregulation of GLUT4 expression on adipocyte cells can result from decreased isoprenoids synthesized. It may result in less insulin-mediated cellular uptake of glucose and show up as glucose intolerance. The

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 1 Jan-Feb 2024, pp: 1346-1350 www.ijprajournal.com ISSN: 2249-7781

downregulation of GLUT4/SLC2A4 in adipocytes has been linked to the acceleration of Type 2 diabetes. B-cells apoptosis can be brought on by cytokineinduced overproduction of NO.

When statins were added to rat pancreatic cells, The stimulation of free cytoplasmic calcium by glucose was inhibited, resulting in a decrease in inulin secretion. Statins also prevent the synthesis of ubiquinone (CoQ10), which lowers ATP production and inhibits insulin secretion. Clinical dosage of atorvastatin resulted in decreased expression of SLC2A4 in both differentiating and mature adipocytes, inhibition of adipocyte differentiation, and impairments in insulin sensitivity and post-challenge glucose intolerance in an animal model of type 2 diabetes. Additionally, it has been demonstrated in animal models that insulin resistance development and statin-induced myopathy are related.



Additional theories regarding the potential impact of statins on diabetes with a recent onset include: reducing the action of small GTPase, inhibiting phosphorylation to interfere with insulins, intracellular signal transduction pathways, decreasing the differentiation of adipocytes to inhibit peroxisome proliferator-activated receptor gamma, and inhibiting leptins to inhibit β-cell proliferation and insulin secretion. Lipophilic statin atorvastatin may reduce insulin secretion because of increased cytotoxicity or HMG CoA inhibition. One can summarize how statins affect the pancreatic beta cells.

VI. USE OF STATINS IN DIABETES

Recommendations for the use of statins in diabetes.

The authors occasionally recommend the use of statins in patients with cardiovascular disease.

In patients with cardiovascular risk factors, statins are eight times more likely to prevent cardiovascular events than cause diabetes, shifting the risk-benefit ratio in favor of statin therapy.

The small increase in blood glucose levels caused by statins is not a problem if it reduces morbidity or mortality from macrovascular and microvascular complications.

In patients with low cardiovascular risk factors, statins should be used with caution, less aggressive LDL-C lowering targets should be maintained, and fasting glucose monitoring should be performed routinely.

In high-risk patients with impaired glucose tolerance and known cardiac risk factors, statins in diuretics increase the risk of developing new-onset diabetes.

Both drugs tend to increase blood sugar levels and require regular monitoring.

Compared to other cardiovascular drugs such as Thiazide diuretics and beta-blockers, statins are onethird less likely to cause diabetes.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 1 Jan-Feb 2024, pp: 1346-1350 www.ijprajournal.com ISSN: 2249-7781

However, Pravastatin should be preferred over other statins.

One meta-analysis comparing high-dose statin therapy with moderate-dose statin therapy found that the former was associated with improved cardiovascular outcomes, but was also associated with a 12% increased risk.

Such studies have raised controversy over the treatment of patients who fail to achieve and target lipid profiles with moderate doses of statins.

As you get older, your risk of diabetes increases and statins may become less effective.

Caution should be taken in such patients.

Factors such as age, weight gain and elevated blood sugar levels before taking statins indicate whether a patient will develop diabetes.

Statin use may detect diabetes in patients with other risk factors. Therefore, these results may be relevant for obese patients and patients with metabolic syndrome.

A meta-analysis of data from over 170,000 individuals from 27 randomized trials also found a benefit risk ratio in favour of statins.

Patients receiving statins had better outcomes after cardiac surgery. Current guidelines recommend the use of statins in patients undergoing coronary artery bypass grafting.

Statins may reduce cardiovascular complications such as atrial fibrillation and myocardial infarction after heart surgery, but at the same time, poor glycemic control may increase risk of non cardiovascular.

The evidence for drugs against this type of dyslipidemia is not as strong as for drugs against LDL-C.

In conclusion, physicians should be aware of the development of diabetes in patients receiving intensive statin therapy.

In patients at low risk for cardiovascular disease, lifestyle management should be considered and the use of statins should be reconsidered.



International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 1 Jan-Feb 2024, pp: 1346-1350 www.ijprajournal.com ISSN: 2249-7781

VII. CONCLUSION

Statins not only combat diabetic dyslipidemia, but also combat microvascular and macrovascular diabetic complications, as well as other complications such as endothelial dysfunction, inflammation, oxidative stress, CKD, NAFLD, Met, OSAS, and hyperuricemia. It has also been shown to have a positive impact on cardiac vascular risk factors. Because statin therapy is associated with a significant reduction in his CVD risk, Their role in the treatment of high risk-patients such as T2DM patients is of particular importance in clinical practice. A moderate statin-associated NOD risk is suggested, but this does not outweigh his CVD risk reduction benefits. Based on the above data, statins are beneficial and should be recommended for patients with T2DM. Secondary prevention for treated high-risk patients is important because effective treatment-to-target approaches are usually not available. Even fewer people with diabetes meet their daily blood sugar, blood pressure, and LDL-C goals. Current clinical data is in order to improve implementation of current guidelines in daily practice and thus improve clinical outcomes.

REFERENCE

[1]. Brouilette SW, Moore JS, Mc Mahon AD, Thompson JR, Ford I, Shepherd J, Packard CJ, Samani NJ. Telomere length, risk of coronary heart diseases, and statin treatment in the west of Scotland primary prevention study: a nested case-control study. Lancet. 2007;369:107-114.

[2]. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, et al. Secondary prevention of cardiovascular events with long-

[3]. term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes care. 2003;26:2713-2721.

[4]. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al.

[5]. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.

[6]. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Lius S, Merriam PA, et al.

[7]. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012;172:144-152.

[8]. Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, Minnemann T, Shulman GI, Kahn BB. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Natre.2001;409:729-733.

[9]. Nakata M, Uto N, Maruyama I, Yada T. Nitric oxide includes apoptosis via Ca2+-dependent processes in the pancreatic beta cell line MIN6. Cell Struct Funct. 1996;24:451-455.

[10]. Shah RV, Goldfine AB. Statins and risk of new-onset diabetes mellitus. Circulation. 2012;126:e282-e284.

[11]. Mancini GB, Hegele RA, Leiter LA. Dyslipidemia. Can J Diabetes. 2013;37 supp11:S110-S116.

[12]. Sun P, Tunceli K, Zhang Q, et al. Time to initiation of oral antihyperglycemic and statin therapy in previously untreated patients with type 2 diabetes in united states. Curr Med Res Opin 2013 Apr 29.

[13]. Wallach-Kildemoes H, Andersen M, Diderichsen F, Lange T. Adherence to preventive statin therapy according to socioeconomic position. Eur J Clin Pharmacol 2013 Apr 16.